Avecho Biotechnology (ASX:AVE) Accounts Payable: A$0.10 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avecho Biotechnology Accounts Payable?

Avecho Biotechnology ASX:AVE -2.44% Accounts Payable is A$0.10 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Avecho Biotechnology's Accounts Payable for the quarter that ended in Dec. 2025 was A$0.10 Mil.

Avecho Biotechnology's quarterly Accounts Payable increased from Dec. 2024 (A$0.06 Mil) to Jun. 2025 (A$0.66 Mil) but then declined from Jun. 2025 (A$0.66 Mil) to Dec. 2025 (A$0.10 Mil).

Avecho Biotechnology's annual Accounts Payable declined from Dec. 2023 (A$0.10 Mil) to Dec. 2024 (A$0.06 Mil) but then increased from Dec. 2024 (A$0.06 Mil) to Dec. 2025 (A$0.10 Mil).

Avecho Biotechnology Accounts Payable Related Terms

Avecho Biotechnology Accounts Payable Historical Data

* Premium members only.

The historical data trend for Avecho Biotechnology's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avecho Biotechnology Accounts Payable Chart

Avecho Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.19 0.10 0.06 0.10

Avecho Biotechnology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.98 0.06 0.66 0.10

Avecho Biotechnology Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$0.10 Mil mean?
Avecho Biotechnology (ASX:AVE) has a Accounts Payable of A$0.10 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Avecho Biotechnology and its competitors.
Is Avecho Biotechnology's Accounts Payable too high?
Avecho Biotechnology's current Accounts Payable is A$0.10 Mil.
How does Avecho Biotechnology's Accounts Payable compare to VRTX and REGN?
Avecho Biotechnology's Accounts Payable of A$0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Avecho Biotechnology and its competitors. Avecho Biotechnology's current Accounts Payable is A$0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Accounts Payable of A$0.10 Mil. The current Accounts Payable is A$0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Accounts Payable is A$0.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avecho Biotechnology Business Description

Other Exchanges OEZ:Germany
Address Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.